Intercell AG

euro adhoc: Intercell AG
Financial Figures/Balance Sheet
Intercell announces Q4 and preliminary full-year 2007 results: First profitable year in company history - Vaccine against Japanese Encephalitis fully on track towards all markets - ...

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

quaterly report


First profitable year in Intercell´s history - Clear growth in revenues and profitability expected for 2008

» EUR 5.0 m net profit and positive operating cash flow of EUR 41.7 m » Revenues of EUR 53.3 m, an increase of 127.5 percent - driven by payments    from strategic alliances » R&D costs of EUR 40.4 m enabled all programs to be progressed forward    at full speed in order to fully take advantage and create the maximum    possible value from the development programs and technology platforms » Strong cash position with EUR 287.6 m - plus, unconditional EUR 40.0 m    payment already committed for 2008 » Clear revenue and profit growth expected in 2008 based on the approval of    the Japanese Encephalitis vaccine and on income from product and technology    partnerships » Given this result and strategy, Intercell joined the ranks of the few    profitable biotechnology companies worldwide

Clear strategy to market for the first product - Intercell´s investigational Japanese Encephalitis vaccine

» Market Authorization Application (MAA) in Europe and Biological License

@@start.t2@@Application (BLA) with the US Food and Drug Administration (FDA) submitted   in December 2007, and already excepted » Licensure application to Australian Therapeutic Goods Administration (TGA)   submitted in February of 2008 » Intercell Biomedical Ltd. (Scotland) received Manufacturer´s License for   commercial manufacturing@@end@@

» FDA pre-approval inspection of the facilities pre-scheduled for April of 2008 » Data from pediatric clinical trials in endemic countries expected within    the next weeks » Intercell´s cooperation with the US Army, geared toward the long-term    supply of the JE-vaccine for the military, is progressing well -    contractual agreement expected latest upon FDA approval

Novartis alliance

» Phase I clinical trial for an improved seasonal Influenza vaccine   formulated with IC31® completed successfully - Intercell´s adjuvant IC31®    demonstrates very good safety and tolerability profile. Novartis will    continue clinical Phase I/II development of IC31® adjuvanted flu vaccines    in 2008 » Joint therapeutic vaccine program against HCV met primary endpoints in    Phase II - data confirms findings of the interim analysis from Q3 2007 -    statistically significant viral load reduction and excellent safety profile    -   further clinical trials in co-development with Novartis to include IC31® » Cooperation with Novartis is based on a major strategic partnership that    was signed in July of 2007

Hospital acquired-infections

» S. aureus vaccine - Merck & Co., Inc. has initiated Phase II clinical    development by the end of 2007. Intercell expects further extension of    clinical program into additional indications in early 2008 » Pseudomonas vaccine - preparations for start of clinical Phase II/III    trials in 2008 underway » Pre-clinical candidates for further nosocomial vaccine and antibody product    targets including Klebsiella have been identified


» Further clinical trials started at the Department of Infectious Diseases    at the Leiden University Medical Center, Netherlands, within the new global    franchise to fight Tuberculosis » Tuberculosis vaccine will be further developed in a collaboration between    Sanofi Pasteur and Statens Serum Institut (SSI) including Intercell´s    adjuvant IC31®, strongly supported by the Aeras Global Tuberculosis    Foundation and the EU

Technology platforms: IC31® & AIP®

» Pneumococcus vaccine candidate funded by PATH on course to entering clinical Phase I trials in 2008 » Developmental programs and partnerships in the field of vaccines and    monoclonal antibodies for Group B Streptococcus and hospital-acquired    infections to be accelerated » New partnerships for adjuvant IC31® and the definition of new vaccine    candidates from AIP® expected for 2008

Management Board

» The Management Board, with Gerd Zettlmeissl as Chief Executive Officer,    Werner Lanthaler as Chief Financial Officer, and Alexander von Gabain as    Chief Scientific Officer appointed for a further three-year term. Thomas    Lingelbach appointed as new member of the Management Board as Chief    Operating Officer.

@@start.t3@@EUR in thousands                                 3 months ended
                                                        Dec 31,        Dec 31,                Year ended

                                                         2007            2006            2007            2006

Revenues                                          40,790         16,970         53,349         23,452

Net profit/(loss)                            27,094          5,618          5,009        (16,143)

Net operating cash flow                  69,268         10,032         41,686         (7,979)
Cash and marketable securities,@@end@@

end of period                                 287,571         94,421        287,571      

For the complete report please see

@@start.t4@@end of announcement                                                 euro adhoc

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Lucia Malfent
Head of Corporate Communications
Campus Vienna Biocenter 2, A-1030 Vienna
P: +43-1-20620-303
Mail to:

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: